Completed OBSERVATIONAL NCT04413929

Study on Safety and Effectiveness of Ergoferon in the Treatment of Flu / ARVI in Outpatients. (HERMITAGE)

International Observational Non-Interventional Retrospective Program for Studying the Efficiency and Safety of Ergoferon in Patients With Influenza and Acute Respiratory Viral Infection (ARVI).

Sponsor: Materia Medica Holding

Conditions Viral Respiratory Infection

Interventions Ergoferon

Updated 7 times since 2020 Last updated: Mar 9, 2021 Started: Oct 31, 2016 Primary completion: Apr 30, 2017 Completion: Apr 30, 2017

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT04413929, this observational or N/A phase trial focuses on Viral Respiratory Infection and remains completed. Sponsored by Materia Medica Holding, it has been updated 7 times since 2016, reflecting limited change activity. This study is part of the global effort to build evidence for infectious disease interventions.

Status Flow

Change History

7 versions recorded

Sep 2024 — Present [monthly]

Completed
Jul 2024 — Sep 2024 [monthly]

Completed
Jan 2023 — Jul 2024 [monthly]

Completed
Dec 2022 — Jan 2023 [monthly]

Completed
May 2021 — Dec 2022 [monthly]

Completed

▶ Show 2 earlier versions

Jan 2021 — May 2021 [monthly]

Completed
Jul 2020 — Jan 2021 [monthly]

Completed

First recorded

Oct 2016

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Materia Medica Holding

Data source: Materia Medica Holding

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

No location information available.